Stephen F Konieczny
Overview
Explore the profile of Stephen F Konieczny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wohner M, Pinter T, Bonelt P, Hagelkruys A, Kostanova-Poliakova D, Stadlmann J, et al.
Front Immunol
. 2023 Jan;
13:859598.
PMID: 36618345
Antibody secretion by plasma cells provides acute and long-term protection against pathogens. The high secretion potential of plasma cells depends on the unfolded protein response, which is controlled by the...
2.
Zhang Z, Cheng L, Li J, Qiao Q, Karki A, Allison D, et al.
Cancer Res
. 2022 Aug;
82(19):3532-3548.
PMID: 35950917
Significance: Inhibition of Plk1 induces upregulation of PD-L1 expression in pancreatic ductal adenocarcinoma, stimulating antitumor immunity and sensitizing tumors to immunotherapy.
3.
Venis S, Moon H, Yang Y, Utturkar S, Konieczny S, Han B
Lab Chip
. 2021 Sep;
21(19):3675-3685.
PMID: 34581719
A pancreatic acinus is a functional unit of the exocrine pancreas producing digest enzymes. Its pathobiology is crucial to pancreatic diseases including pancreatitis and pancreatic cancer, which can initiate from...
4.
Schweickert P, Wang N, Sandefur S, Lloyd M, Konieczny S, Frye C, et al.
Biotechnol J
. 2020 Dec;
16(4):e2000308.
PMID: 33369118
Most biopharmaceuticals produced today are generated using Chinese hamster ovary (CHO) cells, therefore significant attention is focused on methods to improve CHO cell productivity and product quality. The discovery of...
5.
Schweickert P, Yang Y, White E, Cresswell G, Elzey B, Ratliff T, et al.
J Thromb Haemost
. 2020 Oct;
19(1):161-172.
PMID: 33064371
Essentials Elimination of PDAC tumor cell PAR1 increased cytotoxic T cells and reduced tumor macrophages. PAR1 PDAC cells are preferentially eliminated from growing tumors. Thrombin-PAR1 signaling in PDAC tumor cells...
6.
Moon H, Ozcelikkale A, Yang Y, Elzey B, Konieczny S, Han B
Lab Chip
. 2020 Sep;
20(20):3720-3732.
PMID: 32909573
Pancreatic ductal adenocarcinoma (PDAC) is a complex disease with significant intra-tumoral heterogeneity (ITH). Currently, no reliable PDAC tumor model is available that can present ITH profiles in a controlled manner....
7.
Moon H, Ospina-Munoz N, Noe-Kim V, Yang Y, Elzey B, Konieczny S, et al.
PLoS One
. 2020 Jun;
15(6):e0234012.
PMID: 32544183
Understanding progression of breast cancers to invasive ductal carcinoma (IDC) can significantly improve breast cancer treatments. However, it is still difficult to identify genetic signatures and the role of tumor...
8.
Bradney M, Venis S, Yang Y, Konieczny S, Han B
Small
. 2020 Jan;
16(10):e1905500.
PMID: 31997571
Pancreatic ductal adenocarcinoma (PDAC) is a complex, heterogeneous, and genetically unstable disease. Its tumor microenvironment (TME) is complicated by heterogeneous cancer cell populations and strong desmoplastic stroma. This complex and...
9.
Yang Y, Stang A, Schweickert P, Lanman N, Paul E, Monia B, et al.
Cancer Res
. 2019 May;
79(13):3417-3430.
PMID: 31048498
Pancreatic ductal adenocarcinoma (PDAC) is associated with robust activity of the coagulation system. To determine mechanisms by which clotting factors influence PDAC tumor progression, we generated and characterized C57Bl/6-derived KPC...
10.
Shouksmith A, Shah F, Grimard M, Gawel J, Raouf Y, Geletu M, et al.
J Med Chem
. 2019 Feb;
62(5):2651-2665.
PMID: 30776234
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is...